Skip to main content

Table 1 Clinical characteristics of the 454 patients

From: Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma

Sex ratio, female/male 0.96
Mean age (± SD) 65 (± 10)
Mean BMI (± SD) 23.6 (± 4.16)
 < 18.5 (%) 37 (8.2)
 18.5–24.9 (%) 282 (62.1)
 25–29.9 (%) 105 (23.1)
 ≥ 30 (%) 30 (6.6)
Performance status at diagnosis  
 0–1 (%) 397 (87.4)
 2–3 (%) 58 (12.6)
Weight loss  
 Weight loss at diagnosis (%) 294 (64.8)
 Continuous weight loss at restaging (%) 60 (13.2)
Jaundice (%) 264 (58.1)
Biliary stenting (%) 272 (59.9)
Abdominal pain (%) 293 (64.5)
Mean CA 19-9 serum level (UI)(±SD)  
 At diagnosis (after jaundice resolution) 1648 (± 6020)
Tumor location  
 Head (%) 315 (69.4)
 Body (%) 102 (22.5)
 Tail (%) 37 (8.1)
Tumor staging  
 Borderline 336 (74)
 Locally advanced 118 (26)
Induction treatment (%) 454 (100)
 Chemotherapy (%) 375 (82.6)
 Chemoradiation (%) 79 (17.4)
Resection (%) 142 (31.3)
  1. BMI body mass index, CA 19-9 carbohydrate antigene 19-9